Share on LinkedInShare on LinkedIn

ARTICLE · 08 APRIL 2026

Pharma Tariffs Under Section 232 Come With Significant Carveouts

Cassidy Levy Kent LLP
Cassidy Levy Kent LLP
Contributor
Cassidy Levy Kent LLP

Cassidy Levy Kent LLP

Cassidy Levy Kent is an international law firm with offices in Washington, Ottawa, and Brussels....

View firm profile
Explore more from Cassidy Levy Kent LLP

On April 2, 2026, President Trump issued a Proclamation imposing tariffs of up to 100 percent under Section 232 of the Trade Expansion Act of 1962 on certain patented pharmaceuticals and associated pharmaceutical ingredients.

United StatesInternational Law

On April 2, 2026, President Trump issued a Proclamation imposing tariffs of up to 100 percent under Section 232 of the Trade Expansion Act of 1962 on certain patented pharmaceuticals and associated pharmaceutical ingredients.

Rather than imposing a uniform tariff, the Proclamation establishes a differentiated framework that relies upon product type, country of origin, and, in some instances, company-specific commitments relating to U.S. production and pricing.

As a result, impacted stakeholders must pay close attention not only to tariff classification and product origin, but also to upcoming implementation guidance from the Department of Commerce and how this policy interacts with ongoing trade and health policy developments.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from